Universe Pharmaceuticals INC (NASDAQ: UPC), a Chinese pharmaceutical manufacturer and distributor, announced plans for a share consolidation at a ratio of 40 to 1. This consolidation will combine every 40 ordinary shares, each with a par value of US$0.28125, into one ordinary share with a par value of US$11.25. Shareholders will not be required to take any action as the outstanding pre-consolidation shares will automatically be combined and converted.

The share consolidation will take effect on March 24, 2025. Trading will begin on a post-consolidation basis on the Nasdaq Capital Market under the ticker “UPC” with a new CUSIP number of G9442G 138 on March 24, 2025, U.S. Eastern time. No fractional shares will be issued; instead, fractional shares will be rounded up to the nearest whole share. Following the share consolidation, the company’s authorized share capital will consist of US$140,625,000 divided into 11,250,000 ordinary shares, with a par value of US$11.25 each, and 1,250,000 preferred shares, with a par value of US$11.25 each.

About Universe Pharmaceuticals INC

Headquartered in Ji’an, Jiangxi, China, Universe Pharmaceuticals INC is a pharmaceutical company focused on production and distribution in China. The company specializes in the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products for the elderly, aiming to improve their physical well-being during aging. Universe Pharmaceuticals also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements produced by other pharmaceutical companies. The company’s products are currently available in 30 provinces throughout China. Additional details can be found on the company’s website at .

Forward-Looking Statements

This announcement contains forward-looking statements that involve risks and uncertainties. These statements are based on current expectations and projections regarding future events and financial trends that may impact the company’s financial condition, operating results, business strategy, and financial needs. These forward-looking statements can be identified by terms such as “may,” “will,” “expect,” ”anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” and similar expressions. The company is not obligated to update these statements to reflect new events, circumstances, or changes in expectations, except as required by law. While the company believes these expectations are reasonable, it cannot guarantee their accuracy and advises investors that actual results may differ significantly. Investors are encouraged to review other factors that could affect the company’s future performance, as detailed in its registration statement and other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

Ms. Lin Yang
Chief Financial Officer of Universe Pharmaceuticals INC